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ABSTRACT:
Besides their putative usage for therapies, stem cells are a promising tool  for functional 
studies of genes involved in human genetic diseases or oncogenesis. For this purpose 
induced pluripotent stem (iPS) cells can be derived from patients harbouring specific 
mutations. In contrast to adult stem cells, iPS cells are pluripotent and can efficiently 
be grown in culture. However, iPS cells are modulated due to the ectopic induction 
of pluripotency, harbour other somatic mutations accumulated during the life span 
of the source cells, exhibit only imperfectly cleared epigenetic memory of the source 
cell, and are often genomically instable. In addition, iPS cells from patients only allow 
the investigation of mutations, which are not prenatally lethal. Embryonic stem (ES) 
cells have a high proliferation and differentiation potential, but raise ethical issues. 
Human embryos, which are not transferred in the course of in vitro fertilization, 
because of preimplantation genetic diagnosis of a genetic defect, are still rarely 
donated for the establishment of ES cell lines. In addition, their usage for studies 
on gene functions for oncogenesis is hampered by the fact the ES cells are already 
tumorigenic per se. In 2003 amniotic fluid stem (AFS) cells have been discovered, 
which meanwhile have been demonstrated to harbour the potential to differentiate 
into cells of all three germ layers. Monoclonal human AFS cell lines derived from 
amniocenteses have a high proliferative potential, are genomically stable and are 
not associated with ethical controversies. Worldwide amniocenteses are performed 
for routine human genetic diagnosis. We here discuss how generation and banking 
of  monoclonal  human  AFS  cell  lines  with  specific  chromosomal  aberrations  or 
monogenic disease mutations would allow to study the functional consequences 
of  disease  causing  mutations.  In  addition,  recently  a  protocol  for  efficient  and 
highly  reproducible  siRNA-mediated  long-term  knockdown  of  endogenous  gene 
functions in AFS cells was established. Since AFS cells are not tumorigenic, gene 
modulations not only allow to investigate the role of endogenous genes involved 
in human genetic diseases but also may help to reveal putative oncogenic gene 
functions in different biological models, both in vitro and in vivo. This concept is 
discussed and a “proof of principle”, already obtained via modulating genes involved 
in the mammalian target of rapamycin (mTOR) pathway in AFS cells, is presented.  
INTRODUCTION
In medical genetics the future development of new 
prophylactic and therapeutic strategies directly depends 
on a better understanding of the mechanisms by which 
genetic variation contributes to disease. It must be a major 
goal of human genetics to use optimal biological models, 
that allow the investigation of the consequences of a 
specific genetic aberration. On the one hand, in the past a 
powerful approach was the establishment of gain- or loss-
of-function mouse mutants. However, due to fundamental Oncotarget 2011; 2:  705 - 712 706 www.impactjournals.com/oncotarget
biological differences many phenotypes of human genetic 
diseases fail to be successfully replicated in mice. On the 
other hand, human clinical studies can per se also only 
provide limited information: 1) It is almost impossible 
to obtain the specific tissue of interest (e.g. neuronal or 
cardiac cells), given it is not blood. 2) For more detailed 
biochemical and cell biological investigations a distinct 
quantity of material must be available. Unfortunately, long 
expansion of human biopsy material is often accompanied 
by the induction of mutations in cell culture. Accordingly, 
today, human stem cells are in the focus of interest of 
medical genetics [1, 2].
To be useful in medical genetics human stem cells 
must fulfil certain criteria. They should be available with 
specific natural occurring genetic aberrations, which are 
of relevance for certain human pathological phenotypes. 
In addition, they should harbour high proliferative 
activities and pluripotency, the potential to differentiate in 
cells of all three germ layers. Human ES cells are derived 
from the inner cell mass of the blastocyst. They can be 
grown in culture in an undifferentiated state and retain 
their pluripotent differentiation capacity for an unlimited 
period of time. Since over twenty years human embryos 
are diagnosed via preimplantation genetic diagnosis 
in the course of in vitro fertilization. This is offered to 
couples, whose potential offsprings are at risk of single 
gene disorders or structural and numerical chromosome 
aberrations [3]. As a consequence, embryos with all kinds 
of numerical chromosomal abnormalities and unbalanced 
chromosomal  translocations,  as  well  as  with  specific 
monogenic disease mutations are excluded from transfer 
into the uterus and could be used to generate human ES cell 
lines. The top ten of monogenic diseases diagnosed has 
been relatively constant over the years, including cystic 
fibrosis, β-thalassaemia, spinal muscular atrophy, sickle 
cell disease, Huntington´s disease, myotonic dystrophy, 
Charcot-Marie-Tooth disease, fragile X syndrome, 
Duchenne muscular dystrophy and haemophilia [3, 4]. 
In countries, where it is legal to destroy human 
embryos for research, ES cell lines carrying certain 
inherited defects have been generated [see e.g. 5, 6]. 
The fact, that ES cell lines harbouring natural occurring 
mutations have a great potential in the research on the 
pathophysiology of these diseases, as well as for the 
development of new therapies [7], has initiated the 
creation of different registries for human ES cells [8-
10; see also http://www.hescreg.eu]. However, ES cells 
have certain disadvantages. Firstly, destroying a human 
Figure 1: Human AFS cells as a biological model to study gene functions. Monoclonal human AFS cell lines can be established 
from amniocentesis performed because of different medical indications. These stem cell lines can be used for in vitro and in vivo 
investigations of the consequences of the functional loss of specific endogenous genes for differentiation and oncogenic processes. For 
details see the text.
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embryo for research raises ethical issues, regarding when 
human life begins and the moral status of a few-days-old 
embryos. In addition, the spectrum of ES cells carrying 
an inherited defect is limited due to the fact that in vitro 
fertilization with preimplantation genetic diagnosis is 
only rarely applied [11-14]. And last but not least, ES 
cells cannot be used to investigate the role of specific 
mutations in tumorigenesis in in vivo models, since when 
ES cells are transplanted in mice, they are already per se 
tumorigenic [15].
A second stem cell type, which fulfils the criterias 
described above, are iPS cells. In 2006, Yamanaka´s 
group demonstrated for the first time that adult mouse 
fibroblasts  can  be  reprogrammed  to  pluripotent  stem 
cells via ectopic overexpression of the genes Pou5f1, 
Sox2, Klf4 and cMyc, which are known to be expressed 
in ES cells [16]. Such iPS cells can be grown in 
culture maintaining their pluripotency to form all three 
embryonic tissue types. In 2008, the generation of iPS 
cells  from  patients  with  specific  genetic  diseases  was 
first described [17,18]. Inbetween, a variety of iPS lines 
from single-gene disorders, chromosome syndromes and 
complex diseases, including e.g. amyotrophic lateral 
sclerosis, diabetes mellitus, Parkinson´s diseases, Down 
syndrome, epidermolysis bullosa, or Rett syndrome, have 
been generated [1, 2, 17-20]. Still, iPS cells also harbour 
relevant disadvantages. Using cells from adult patients 
has the advantage that the detailed clinical history of the 
patient is known, but one must take into account that such 
cells might have already accumulated other mutations 
without relevance for the disease of interest. And clearly, 
such an approach only allows to study mutations, which 
are not prenatally lethal. Importantly, the process of ectopic 
induction of pluripotency might also negatively affect the 
usefulness of these cells as models for human diseases 
[1, 2, 19, 20]. In addition, recently it was demonstrated 
that the epigenetic memory of the original differentiated 
state is not perfectly erased during reprogramming [21, 
22]. And finally, it seems to be inevitable that iPS cells 
accumulate karyotypic abnormalities and gene mutations 
during propagation in culture [23-26]. We here discuss 
that human AFS cells might be a powerful alternative for 
disease modelling.
HUMAN AFS CELLS TO STUDY  
NATURAL OCCURRING DISEASE 
CAUSING MUTATIONS
Ultrasound investigations and maternal serum 
screening are routinely used in prenatal diagnosis. 
Specific ultrasound signs and/or maternal age are classical 
indications for invasive genetic prenatal diagnosis, mostly 
to detect fetal numerical chromosomal aberrations. 
Invasive prenatal diagnosis is also recommended to 
detect unbalanced segregation of e.g. balanced parental 
chromosome translocations. In addition, prenatal 
chromosome testing also leads to the detection of a major 
category of “unexpected” chromosomal abnormalities, 
including numerical aneuploidies other than trisomies 
13, 18, and 21, and the wide variety of possible de novo 
structural chromosomal aberrations. Since the Human 
Genome Project was officially launched the knowledge 
on single-gene disorders has grown dramatically. Today, 
a wide variety of mutations, causatively involved in 
monogenic diseases, can be prenatally diagnosed. 
Predominantly such prenatal diagnoses are performed as 
a consequence of a specific family history (Figure 1) [27-
29]. Besides other invasive approaches, amniocentesis 
is a widespreadly accepted standard procedure of care 
since the 1970s. It is almost unpredictable how many 
amniocenteses are worldwide performed per year. An 
older study reported that more than 200.000 amniocentesis 
procedures were performed already 20 years ago, only in 
one year (1990) and only in the United States [30, 31]. 
Despite this wide and well established usage of 
human amniotic fluid cells in routine prenatal diagnosis, 
the knowledge about the cells contained in amniotic fluid 
remained rather elusive [32, 33]. New interest in these 
cells was initiated in 2001, when Fauza´s group reported 
that amniotic fluid cells could be used in tissue engineering 
approaches for the surgical repair of congenital anomalies 
in the perinatal period [34]. This was also about the time 
when  the  first  suggestion  of  human  amniotic  fluid  as 
a new putative source for stem cells was reported [35]. 
In 2003, a highly proliferative cell type, expressing the 
pluripotent stem cell marker Oct4, was discovered to exist 
in human amniotic fluid, providing the first evidence for 
AFS cells [36]. The confirmation of Oct4-positive cells 
in amniotic fluid by different other groups then initiated 
a fast growing stem cell research field [37-45]. In the last 
years, it became evident that AFS cells can differentiate 
into cells of all three embryonic tissue types. AFS cell 
differentiation e.g. upon hematopoietic, neurogenic, 
osteogenic, chondrogenic, adipogenic, renal and hepatic 
lineages has been demonstrated [37-63]. Descending 
from one single Oct4- and NANOG-positive AFS cell, 
it was possible to induce adipogenic, osteogenic and 
neurogenic differentiation [47]. In another study, isolation 
of monoclonal AFS cells, which expressed the markers 
Oct4  and  CD117  (c-kit),  allowed  to  demonstrate  that 
adipogenic, osteogenic, myogenic, endothelial, neurogenic 
and hepatic cell differentiation could be induced [42]. 
Monoclonal human AFS cells can form embryoid bodies 
(EBs) when cultured without anti-differentiation factors 
under conditions in which they are unable to attach 
to the surface of culture dishes and without contact to 
feeder cells. The formation of such three-dimensional 
multicellular aggregates is accompanied by a decrease 
of stem cell marker expression and by the induction of 
differentiation into different lineages [64].
Taken together, these findings prove that human AFS 
cells are pluripotent and able to form embryoid bodies Oncotarget 2011; 2:  705 - 712 708 www.impactjournals.com/oncotarget
and to differentiate into cell types of all three germ layers. 
These data were obtained using monoclonal human AFS 
cell lines generated via magnetic cell sorting and minimal 
dilution approaches from amniocentesis samples. So 
established monoclonal lines can be expanded as immature 
stem cells with high proliferation rate in culture without 
the need of feeder cells [42, 60, 61, 64]. We here suggest 
the generation and banking of normal human AFS cell 
lines, of AFS cell lines with chromosomal aberrations, as 
well as of AFS cell lines with specific monogenic disease 
mutations for research purposes (Figure 1). Such lines 
carrying natural occurring mutations could provide an 
optimal tool for disease modelling with the aim to obtain 
more detailed insights into the functions of the involved 
chromosomal regions or genes. As in the past already 
performed with normal monoclonal human AFS cell lines 
[42, 58, 60, 61, 63, 64], lines harbouring mutations could 
be investigated in in vitro differentiation experiments 
(including  e.g.  organotypic  reaggregation  assays,  see 
below), in embryoid body formation assays, and could 
be investigated in mouse models in vivo (Figure 1). Adult 
stem cells exhibit lower differentiation potential than AFS 
cells and cannot be grown with high proliferative activity. 
Compared to ES cells, AFS cells do not raise ethical issues 
and the spectrum of samples with pathogenic mutations 
should be larger. Compared to iPS cells, there is no need for 
ectopic induction of pluripotency in AFS cells. They are 
genomically stable, they do neither harbour the epigenetic 
memory nor somatic mutations of already differentiated 
source cells, and mutations, which allow implantation 
but are not compatible with a prenatal development until 
birth, could also be included [1, 12, 19, 20, 42-45, 55-
57, 60, 63-65]. Accordingly, AFS cells could provide an 
optimal tool for basic research and disease modelling in 
medical genetics (Figure 1).
HUMAN AFS CELLS TO INVESTIGATE 
GENES INVOLVED IN ONCOGENESIS
Stem cells could also be a powerful tool to study the 
consequences of genetic modulations for transformation 
processes, both, in vitro e.g. in colony formation assays 
and in vivo in mouse models (Figure 1). Such approaches 
are hampered when the chosen stem cell type, in its 
undifferentiated form, is tumorigenic per se. This holds 
true for ES cells [1, 13-15]. Similarly, in the study 
describing  the  first  generation  of  iPS  cells  the  authors 
reported that subcutaneous transplantation of these stem 
cells into nude mice also resulted in tumor development 
[16]. Recently, it became clear that the tumor-forming 
propensities of the many different types of iPS cells vary 
significantly. This is due to the different methods used for 
reprogramming (the genes or proteins, which have been 
modulated), the different iPS cells´ tissues of origin, the 
different genetic background of the donor (including the 
somatic mutations accumulated during the life span of the 
source cell), and very likely also to the propensity of iPS 
cells to accumulate mutations during cultivation [1, 19, 
66, 67]. Accordingly, although the question whether ES 
or iPS cells, after differentiation along specific lineages, 
could be used for studies on transformation processes 
still needs to be further investigated, it is obvious that 
such experimental approaches would have to face many 
difficulties and limitations, which might negatively affect 
the level of interpretation.
 AFS cells are primary cells of a very early stage 
of human development. Accordingly, they very likely did 
not have time to accumulate many somatic mutations yet 
[44, 45, 55-57]. In addition, the investigations performed 
so far revealed that monoclonal human AFS cell lines 
maintain genome stability during expansion [42, 64]. 
And most importantly, AFS cells, unlike ES and iPS 
cells, do not induce tumor formation in severe combined 
immunodeficient mice [42]. Accordingly, we here want to 
suggest the usage of different AFS cell lines to investigate 
the role of specific genetic modulations for transformation 
processes and tumor development (Figure 1). Although 
possible, we would not favour the ectopic expression 
of oncogenes in AFS cells, because of the risk that the 
so obtained high ectopic levels of expression would not 
necessarily mimick a natural occurring situation. We 
rather want to suggest the usage of siRNA-mediated 
knockdown of endogenous tumor suppressor genes (for 
examples see below). Monoclonal human AFS cells with 
so downregulated endogenous gene functions could then 
be investigated in in vitro and in vivo transformation assays 
as indicated in Figure 1. For this purpose we have recently 
established  a  protocol  for  efficient  siRNA-mediated 
prolonged gene silencing in AFS cells. This protocol 
allows a 96-98% downregulation of the endogenous 
expression of tumor suppressors, such as the TSC2 gene 
product tuberin or the cyclin-dependent kinase inhibitor 
p27, over a time period of about 14 days [68].
MODULATION OF MTOR CASCADE 
COMPONENTS IN HUMAN AFS CELLS
Very recently we already made use of the approach 
discussed above to functionally investigate the role of 
components of the mTOR signalling cascade in human 
AFS cells. mTOR is the key component of the insulin 
signalling cascade, which is involved in a wide variety 
of different processes such as cell growth, proliferation, 
metabolism, transcription, translation, survival, autophagy, 
aging, differentiation and oncogenesis. An important 
upstream  regulator  of  mTOR  is  the  oncogenic  kinase 
Akt, which itself is activated via the enzyme cascade 
of  PI3K  (phosphatidylinositol-3-kinase)  and  PDK1 
(phosphoinositide-dependent  kinase-1).  Akt-triggered 
phosphorylation of the tumor suppressor protein tuberin 
(TSC2)  downregulates  its  GTPase-activating  potential 
toward Rheb, which is a potent regulator of mTOR. In Oncotarget 2011; 2:  705 - 712 709 www.impactjournals.com/oncotarget
mammalian cells, two mTOR containing complexes are 
described,  mTORC1  (consisting  of  mTOR,  raptor  and 
mLST8) and mTORC2 (containing mTOR, mLST8, rictor 
and sin1). mTORC1 is involved in the control of mRNA 
translation e.g. via phosphorylating the p70S6Kinase, 
whereas mTORC2 phosphorylates and activates Akt [69-
72]. Deregulation of upstream regulators of mTOR, such 
as e.g. Wnt, Ras, TNF-α, PI3K, or Akt is a hallmark in 
many human cancers. Mutations in the mTOR pathway 
component genes TSC1, TSC2, LKB1, PTEN, VHL, NF1 
and PKD1 trigger the development of the human genetic 
syndromes Tuberous sclerosis, Peutz-Jeghers syndrome, 
Cowden syndrome, Bannayan-Riley-Ruvalcaba 
syndrome, Lhermitte-Duclos disease, Proteus syndrome, 
von  Hippel-Lindau  disease,  Neurofibromatosis  type  1, 
and Polycystic kidney disease. Besides a variety of single 
gene disorders and tumorigenesis, the mTOR pathway has 
also been shown to be of relevance for the development of 
complex diseases, such as cardiac hypertrophy, obesity or 
type 2 diabetes [73-75].
Studies performed in hematopoietic stem cells 
provided first evidence that mTOR might also play a role 
in stem cell physiology [76]. A major characteristic of 
pluripotent stem cells is their potential to spontaneously 
form EBs. EB formation is a commonly used in vitro 
approach to recapitulate and investigate the three-
dimensional and tissue level contexts of the cell 
differentiation phenomena mimicking early mammalian 
embryogenesis [77, 78]. Since it was already earlier shown 
that the mTOR cascade is fully active in human AFS cells 
[79], we induced EB formation of monoclonal human 
AFS cell lines to investigate the role of mTOR. siRNA-
mediated knockdown of raptor or rictor demonstrated that 
EB formation depends on both, mTORC1 and mTORC2 
[64]. Together with similar results in human ES cells [80], 
these findings were the first demonstration of the role of 
mTOR for EB formation of pluripotent stem cells. 
We have further shown that human monoclonal AFS 
cells are able to contribute to the formation process of 
renal tissues. For this purpose, murine embryonic kidneys 
were dissociated into a single-cell suspension and then 
reaggregated to form organotypic renal structures. Using 
this approach it was possible to form chimeric renal 
structures via mixing murine embryonic kidney cells with 
monoclonal human AFS cells selected from amniocentesis 
samples.  Monoclonal,  pluripotent  Oct4-  and  CD117-
positive AFS cells were able to participate in the formation 
process of different renal tissues accompanied by the 
induction of the expression of well known renal markers 
[60]. In this study the highly efficient and reproducible 
protocol for prolonged siRNA-mediated gene silencing in 
human monoclonal AFS cells [68], which was used for the 
EB study described above, also allowed to demonstrate 
the  pivotal  role  of  mTOR  component  genes  for  renal 
tissue formation [60]. 
Taken together the approach of siRNA-mediated 
knockdown of mTOR cascade components in monoclonal 
human AFS cell lines allowed to study the consequences 
on EB formation and on the potential to differentiate along 
renal lineages. These investigations already provided a 
“proof of principle” for the here discussed usage of human 
AFS cells as a model for functional studies of specific 
genes.
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